Financial Management is the Key Strategy for SustainabilityThis financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718 publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each industry are also highlighted.The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include:'The global economic slowdown'Regulatory compliance'Reducing profitability'Increasing R&D costs'Pricing pressures'Counterfeit business Financial Analysis of the Pharmaceutical and Biotechnology Industry1. Margin Analysis'The pharmaceutical industry has generally witnessed smaller margins due to increasing competition from generics, pricing pressures, and decreasing healthcare spending.'In the biotechnology industry, companies within low revenue range and relatively new products have witnessed negative margins because of the heavy investment in R&D and SG&A (selling and general expenses).2. Profitability Analysis'Companies with a large portfolio of drugs have seen higher profitability in the pharmaceutical industry.'The long timelines and accumulating expenditures incurred before a drug is commercialized is making the biotechnology industry less profitable in initial years, even resulting in negative margins for companies that are smaller in terms of revenue. 3. Turnover Analysis'In both the pharmaceutical and biotechnology industries, companies with lower revenue had poor turnover ratios because of the huge investments made in assets and in the development of the product. 4. Cash Reserve Analysis'In the pharmaceutical industry the smaller companies in terms of revenue are increasing their cash reserve as a percentage of their assets.'In the biotechnology industry, both small and large companies in terms of revenue are increasing their cash reserve as a percentage of their assets. 5. R&D to Sales Ratio'Both the pharmaceutical and biotechnology industries did not witness a great variation in the R&D to sales ratio in 2011 compared to the previous year. Though there was a general decline in the overall sales in both the pharmaceutical and biotechnology industries, the R&D expenses were not considerably reduced.Who Will Benefit''Pharmaceutical & biotechnology companies'Private equity'Venture capital investors'Fund managers'Retail investors'Sovereign wealth funds'Hedge funds'Insurance funds and other members of the investing community

1. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Financial Assessment of the Global Pharmaceutical and
Biotechnology Industry
Published on February 2013
Report Summary
Financial Management is the Key Strategy for Sustainability
This financial assessment study analyzes the financial ratios of public companies across the globe in the pharmaceutical and
biotechnology industry. The research objectives are to rank companies based on their financial and risk management while also
identifying key trends that can impact the performance of industry participants over the next year. Those analyzed include 718
publicly-listed pharmaceutical and 482 publicly-listed biotechnology companies across the globe. To assess the financial
performance, ratios are divided into four categories: profitability, liquidity, activity (turnover), and solvency. Top performers in each
industry are also highlighted.
The Key Issues/Challenges Faced by Industry Participants in the Pharmaceutical and Biotechnology Industry Include:
'The global economic slowdown
'Regulatory compliance
'Reducing profitability
'Increasing R&D costs
'Pricing pressures
'Counterfeit business
Financial Analysis of the Pharmaceutical and Biotechnology Industry
1. Margin Analysis
'The pharmaceutical industry has generally witnessed smaller margins due to increasing competition from generics, pricing pressures,
and decreasing healthcare spending.
'In the biotechnology industry, companies within low revenue range and relatively new products have witnessed negative margins
because of the heavy investment in R&D and SG&A (selling and general expenses).
2. Profitability Analysis
'Companies with a large portfolio of drugs have seen higher profitability in the pharmaceutical industry.
'The long timelines and accumulating expenditures incurred before a drug is commercialized is making the biotechnology industry
less profitable in initial years, even resulting in negative margins for companies that are smaller in terms of revenue.
3. Turnover Analysis
'In both the pharmaceutical and biotechnology industries, companies with lower revenue had poor turnover ratios because of the huge
investments made in assets and in the development of the product.
4. Cash Reserve Analysis
'In the pharmaceutical industry the smaller companies in terms of revenue are increasing their cash reserve as a percentage of their
assets.
'In the biotechnology industry, both small and large companies in terms of revenue are increasing their cash reserve as a percentage
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry (From Slideshare) Page 1/4

2. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
of their assets.
5. R&D to Sales Ratio
'Both the pharmaceutical and biotechnology industries did not witness a great variation in the R&D to sales ratio in 2011 compared to
the previous year. Though there was a general decline in the overall sales in both the pharmaceutical and biotechnology industries,
the R&D expenses were not considerably reduced.
Who Will Benefit'
'Pharmaceutical & biotechnology companies
'Private equity
'Venture capital investors
'Fund managers
'Retail investors
'Sovereign wealth funds
'Hedge funds
'Insurance funds and other members of the investing community
Table of Content
Table Of Contents
1. Executive Summary
2. Definition of Key Terms
3. Research Objective and Scope
4. Research Methodology
5. Key Issues/Challenges Faced by Industry Participants
6. Pharmaceutical Industry
7. Top Performers in the Pharmaceutical Industry
8. Biotechnology Industry
9. Top Performers in the Biotechnology Industry
10. The Frost & Sullivan Story
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry (From Slideshare) Page 2/4

3. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Formats
Please select the product formats and the quantity you require.
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry
Site License--USD 6 000.00 Quantity: _____
Site License+Hardcopy--USD 6 500.00 Quantity: _____
Corporate License--USD 7 500.00 Quantity: _____
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry (From Slideshare) Page 3/4

4. ReportLinker Find Industry reports, Company profiles
and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Customer signature:
Financial Assessment of the Global Pharmaceutical and Biotechnology Industry (From Slideshare) Page 4/4